Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 200 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Impact of HIV-1 and Aging on Mucosal Vaccine Responses

NCT03729778
Conditions
HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS, HIV Infections
Interventions
Prevnar-13
Biological
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
21 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

NCT04168190
Conditions
Pneumonia, Pneumococcal
Interventions
V116, Pneumovax™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
20
States / cities
Birmingham, Alabama • Mesa, Arizona • Coral Gables, Florida + 15 more
Conditions
Healthy
Interventions
pneumococcal vaccination (Pneumovax)
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,515 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
38
States / cities
Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more
Completed No phase listed Observational Results available

Impact of Prevnar 13 on Ear Infections in Children

NCT01272999
Conditions
Acute Otitis Media, Mastoiditis
Interventions
No intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 5 more
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of wSp Vaccine in Young Children

NCT07216430
Conditions
Acute Otitis Media (AOM)
Interventions
wSp vaccine, Saline (0.9% NaCl)
Biological
Lead sponsor
Serum Life Science Europe GmbH
Industry
Eligibility
5 Months to 7 Months
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
7
States / cities
Pittsford, New York • Rochester, New York
Conditions
Pneumococcal Infections
Interventions
PCV7 + PPV23, 2 months, PCV7 + PPV23, 6 months
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
55 Years to 70 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Anchorage, Alaska
Conditions
Pneumococcal Infections
Interventions
Multivalent, Tdap, polysaccharide
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Cerritos, California • Savannah, Georgia + 12 more
Conditions
Pneumococcal Infections
Interventions
Tetanus-diphtheria toxoids (Td), 7-valent pneumococcal conjugate vaccine, 23-valent polysaccharide vaccine
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
50 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants

NCT06524414
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC), 15-valent pneumococcal conjugate vaccine (PCV15)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
605 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
61
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • La Puente, California + 39 more
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
22
States / cities
Downey, California • Huntington Beach, California • San Diego, California + 18 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

NCT04526574
Conditions
Pneumococcal Disease
Interventions
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC), Saline, Influenza vaccine
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
1,796 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
63
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 53 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

NCT00500266
Conditions
Pneumococcal Infections
Interventions
13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
68 Years and older
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
40
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 33 more
Conditions
Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
Interventions
Antibiotic
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
34
States / cities
Los Angeles, California • Jacksonville, Florida • Naples, Florida + 29 more
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Conditions
Pneumococcal Disease
Interventions
Candidate-1, Candidate-2, Candidate-3, Candidate-4, Candidate-5, Candidate-6, Candidate Control, 13vPnC, PCV15
Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
18
States / cities
Tustin, California • Walnut Creek, California • Milford, Connecticut + 12 more
Conditions
Pneumonia, Pneumococcal, Diabetes Mellitus, Breast Cancer, Colorectal Cancer
Interventions
Text message nudge
Behavioral
Lead sponsor
Mitesh Patel
Industry
Eligibility
18 Years and older
Enrollment
29,334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.

NCT04583618
Conditions
Pneumococcal Immunization
Interventions
Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb, Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI, Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VII, Pneumococcal 13 - valent conjugate vaccine-Prevnar 13, Pneumococcal Vaccine Polyvalent-Pneumovax 23
Biological
Lead sponsor
Sanofi
Industry
Eligibility
50 Years to 84 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
17
States / cities
Anaheim, California • Rolling Hills Estates, California • Wheat Ridge, Colorado + 14 more
Conditions
Pneumonia, Pneumococcal, Vaccines, Pneumococcal
Interventions
Urine sample collection
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Mobile, Alabama • La Mesa, California • Tampa, Florida + 9 more
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
652 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
15
States / cities
Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more
Completed No phase listed Observational Results available

Vaccine Immune Recovery After Leukemia

NCT05622682
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Observational only: Serology and flow cytometry for ALL cohort participants, Observational only: Infection rates
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
3 Years to 31 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Chicago, Illinois • Grand Rapids, Michigan • Philadelphia, Pennsylvania + 3 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)

NCT03950622
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13®
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
14
States / cities
Mesa, Arizona • San Diego, California • Hialeah, Florida + 10 more